Vaxcyte's (PCVX) "Buy" Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Vaxcyte (NASDAQ:PCVX - Free Report) in a research report released on Wednesday morning, Benzinga reports. They currently have a $140.00 target price on the stock.

Several other analysts have also issued reports on PCVX. Leerink Partners increased their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a report on Tuesday, September 3rd. BTIG Research raised their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Mizuho boosted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 10th. Jefferies Financial Group raised their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Finally, Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Stock Down 3.2 %

Shares of Vaxcyte stock traded down $3.49 during midday trading on Wednesday, hitting $104.07. The company's stock had a trading volume of 2,681,383 shares, compared to its average volume of 837,683. The stock has a 50-day simple moving average of $110.06 and a 200-day simple moving average of $86.69. The firm has a market capitalization of $11.62 billion, a P/E ratio of -22.62 and a beta of 1.01. Vaxcyte has a 1-year low of $46.16 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same period last year, the company posted ($0.91) earnings per share. As a group, sell-side analysts predict that Vaxcyte will post -4.33 earnings per share for the current year.

Insider Transactions at Vaxcyte

In related news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now owns 12,723 shares of the company's stock, valued at $1,369,885.41. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Vaxcyte news, CEO Grant Pickering sold 7,098 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $109.21, for a total transaction of $775,172.58. Following the sale, the chief executive officer now directly owns 138,581 shares of the company's stock, valued at approximately $15,134,431.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the sale, the senior vice president now owns 12,723 shares in the company, valued at $1,369,885.41. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 115,098 shares of company stock valued at $12,394,473. 3.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Riverview Trust Co acquired a new position in shares of Vaxcyte during the third quarter valued at $27,000. Fifth Third Bancorp bought a new position in shares of Vaxcyte in the 2nd quarter valued at about $35,000. Fidelis Capital Partners LLC acquired a new stake in shares of Vaxcyte during the 1st quarter worth approximately $37,000. Blue Trust Inc. raised its stake in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after buying an additional 93 shares during the last quarter. Finally, J.Safra Asset Management Corp raised its stake in shares of Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock worth $46,000 after buying an additional 526 shares during the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.